RNA, U6atac small nuclear 12, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6ATAC12P profile across patient tissues and cancer cell-line models. RNU6ATAC12P expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RNU6ATAC12P is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, RNU6ATAC12P RNA expression shows 8,810 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, LUAD, and GBM as cancer lineages where RNU6ATAC12P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6ATAC12P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6ATAC12P survival associations across molecular data types. RNU6ATAC12P RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6ATAC12P RNA expression–survival associations across cancer types. High RNU6ATAC12P expression shows unfavorable associations in SKCM, LUSC, HNSC, LIHC, LAML and STAD. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RNU6ATAC12P RNA expression.
This table summarizes RNU6ATAC12P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6ATAC12P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6ATAC12P shows lower tumor expression in LUAD and LUSC. The LUAD box plot shows higher RNU6ATAC12P RNA expression in normal versus tumor tissue (log2 FC = −0.557, t-test p = .006).
This table shows molecular features associated with RNU6ATAC12P in patient tissues and cancer cell lines. In patient samples, RNU6ATAC12P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
